Getinge AB (publ) (GETI-B.ST)
SEK 174.85
(2.01%)
SEK 174.85
(2.01%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 10.75 Billion SEK | 0.94% |
| 2022 | 9.52 Billion SEK | 2.29% |
| 2021 | 9.31 Billion SEK | -4.58% |
| 2020 | 9.76 Billion SEK | 0.02% |
| 2019 | 9.75 Billion SEK | -13.92% |
| 2018 | 11.33 Billion SEK | 35.84% |
| 2017 | 8.34 Billion SEK | -18.33% |
| 2016 | 10.21 Billion SEK | -4.89% |
| 2015 | 10.74 Billion SEK | 15.98% |
| 2014 | 9.26 Billion SEK | 3.37% |
| 2013 | 8.96 Billion SEK | 5.81% |
| 2012 | 8.47 Billion SEK | 16.0% |
| 2011 | 7.3 Billion SEK | -2.67% |
| 2010 | 7.5 Billion SEK | -4.91% |
| 2009 | 7.88 Billion SEK | 217.55% |
| 2008 | -6.71 Billion SEK | -223.86% |
| 2007 | 5.41 Billion SEK | 30.65% |
| 2006 | 4.14 Billion SEK | 13.15% |
| 2005 | 3.66 Billion SEK | 10.35% |
| 2004 | 3.32 Billion SEK | -38.17% |
| 2003 | 5.37 Billion SEK | 10.42% |
| 2002 | 4.86 Billion SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 2.75 Billion SEK | 4.64% |
| 2024 Q3 | 3.21 Billion SEK | 22.49% |
| 2024 Q1 | 2.63 Billion SEK | -3.77% |
| 2023 Q1 | 2.59 Billion SEK | -6.41% |
| 2023 Q4 | 2.73 Billion SEK | 26.06% |
| 2023 Q3 | 2.16 Billion SEK | -18.43% |
| 2023 Q2 | 2.65 Billion SEK | 2.31% |
| 2023 FY | 9.61 Billion SEK | 0.94% |
| 2022 Q2 | 2.23 Billion SEK | -0.8% |
| 2022 Q1 | 2.25 Billion SEK | -25.65% |
| 2022 FY | 9.52 Billion SEK | 2.29% |
| 2022 Q4 | 2.77 Billion SEK | 22.89% |
| 2022 Q3 | 2.25 Billion SEK | 0.98% |
| 2021 Q1 | 2.03 Billion SEK | -20.2% |
| 2021 FY | 9.31 Billion SEK | -4.58% |
| 2021 Q2 | 2.21 Billion SEK | 8.87% |
| 2021 Q3 | 2.04 Billion SEK | -7.65% |
| 2021 Q4 | 3.03 Billion SEK | 48.6% |
| 2020 Q3 | 2.21 Billion SEK | -12.55% |
| 2020 FY | 9.76 Billion SEK | 0.02% |
| 2020 Q2 | 2.53 Billion SEK | 2.63% |
| 2020 Q1 | 2.46 Billion SEK | -2.06% |
| 2020 Q4 | 2.54 Billion SEK | 14.85% |
| 2019 Q4 | 2.52 Billion SEK | 2.82% |
| 2019 Q3 | 2.45 Billion SEK | 0.53% |
| 2019 Q1 | 2.35 Billion SEK | -2.61% |
| 2019 FY | 9.75 Billion SEK | -13.92% |
| 2019 Q2 | 2.43 Billion SEK | 3.74% |
| 2018 Q3 | 4.12 Billion SEK | 84.44% |
| 2018 FY | 11.33 Billion SEK | 35.84% |
| 2018 Q1 | 2.56 Billion SEK | 1019.65% |
| 2018 Q2 | 2.23 Billion SEK | -12.79% |
| 2018 Q4 | 2.41 Billion SEK | -41.49% |
| 2017 Q4 | 229 Million SEK | -91.51% |
| 2017 Q3 | 2.69 Billion SEK | -2.28% |
| 2017 FY | 8.34 Billion SEK | -18.33% |
| 2017 Q2 | 2.76 Billion SEK | 3.88% |
| 2017 Q1 | 2.65 Billion SEK | 1.68% |
| 2016 Q4 | 2.61 Billion SEK | 5.06% |
| 2016 Q1 | 2.56 Billion SEK | -5.77% |
| 2016 Q2 | 2.55 Billion SEK | -0.43% |
| 2016 FY | 10.21 Billion SEK | -4.89% |
| 2016 Q3 | 2.48 Billion SEK | -2.55% |
| 2015 FY | 10.74 Billion SEK | 15.98% |
| 2015 Q4 | 2.72 Billion SEK | 4.49% |
| 2015 Q3 | 2.6 Billion SEK | -7.2% |
| 2015 Q2 | 2.8 Billion SEK | 7.3% |
| 2015 Q1 | 2.61 Billion SEK | 10.34% |
| 2014 Q1 | 2.25 Billion SEK | 3.02% |
| 2014 FY | 9.26 Billion SEK | 3.37% |
| 2014 Q4 | 2.37 Billion SEK | 2.91% |
| 2014 Q3 | 2.3 Billion SEK | -1.5% |
| 2014 Q2 | 2.33 Billion SEK | 3.73% |
| 2013 Q4 | 2.18 Billion SEK | -0.5% |
| 2013 FY | 8.96 Billion SEK | 5.81% |
| 2013 Q3 | 2.19 Billion SEK | -3.09% |
| 2013 Q2 | 2.26 Billion SEK | -1.6% |
| 2013 Q1 | 2.3 Billion SEK | 2.9% |
| 2012 Q2 | 2.13 Billion SEK | 4.34% |
| 2012 Q3 | 2.03 Billion SEK | -4.68% |
| 2012 Q4 | 2.24 Billion SEK | 9.91% |
| 2012 FY | 8.47 Billion SEK | 16.0% |
| 2012 Q1 | 2.05 Billion SEK | 1.38% |
| 2011 Q3 | 1.72 Billion SEK | -2.1% |
| 2011 FY | 7.3 Billion SEK | -2.67% |
| 2011 Q1 | 1.79 Billion SEK | -5.97% |
| 2011 Q4 | 2.02 Billion SEK | 17.22% |
| 2011 Q2 | 1.76 Billion SEK | -1.78% |
| 2010 Q3 | 1.78 Billion SEK | -9.44% |
| 2010 Q2 | 1.97 Billion SEK | 7.24% |
| 2010 Q1 | 1.83 Billion SEK | -8.78% |
| 2010 FY | 7.5 Billion SEK | -4.91% |
| 2010 Q4 | 1.9 Billion SEK | 6.89% |
| 2009 FY | 7.88 Billion SEK | 217.55% |
| 2009 Q3 | 1.88 Billion SEK | -4.85% |
| 2009 Q4 | 2.01 Billion SEK | 6.9% |
| 2009 Q1 | 2.01 Billion SEK | 0.0% |
| 2009 Q2 | 1.98 Billion SEK | -1.44% |
| 2008 FY | -6.71 Billion SEK | -223.86% |
| 2007 FY | 5.41 Billion SEK | 30.65% |
| 2006 FY | 4.14 Billion SEK | 13.15% |
| 2005 FY | 3.66 Billion SEK | 10.35% |
| 2004 FY | 3.32 Billion SEK | -38.17% |
| 2003 FY | 5.37 Billion SEK | 10.42% |
| 2002 FY | 4.86 Billion SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Acarix AB (publ) | 82.85 Million SEK | -12886.119% |
| ADDvise Group AB (publ) | 611.8 Million SEK | -1658.581% |
| ADDvise Group AB (publ) | 611.8 Million SEK | -1658.581% |
| Arcoma AB | 53.25 Million SEK | -20103.936% |
| Bactiguard Holding AB (publ) | 4.96 Million SEK | -216422.439% |
| BICO Group AB (publ) | 2.84 Billion SEK | -277.721% |
| Boule Diagnostics AB (publ) | 210.44 Million SEK | -5012.524% |
| CellaVision AB (publ) | 295.99 Million SEK | -3534.92% |
| Clinical Laserthermia Systems AB (publ) | 68.93 Million SEK | -15508.588% |
| Chordate Medical Holding AB (publ) | 1.3 Million SEK | -821710.243% |
| C-Rad AB (publ) | 3.8 Million SEK | -283031.579% |
| Duearity AB (publ) | 21.58 Million SEK | -49744.8% |
| Dignitana AB (publ) | 74.73 Million SEK | -14296.007% |
| Episurf Medical AB (publ) | 2.7 Million SEK | -398381.481% |
| Scandinavian Real Heart AB (Publ) | 18.22 Million SEK | -58922.764% |
| Iconovo AB (publ) | 63.35 Million SEK | -16882.241% |
| Integrum AB (publ) | 90.57 Million SEK | -11779.011% |
| Luxbright AB (publ) | 23.09 Million SEK | -46494.884% |
| Mentice AB (publ) | 237.06 Million SEK | -4438.513% |
| OssDsign AB (publ) | 175.6 Million SEK | -6026.958% |
| Paxman AB (publ) | 133.8 Million SEK | -7941.106% |
| Promimic AB (publ) | 48.55 Million SEK | -22059.746% |
| Qlife Holding AB (publ) | 162.38 Million SEK | -6525.612% |
| SciBase Holding AB (publ) | 69.97 Million SEK | -15275.272% |
| ScandiDos AB (publ) | 61.03 Million SEK | -17526.724% |
| Sectra AB (publ) | 39.06 Million SEK | -27442.687% |
| Sedana Medical AB (publ) | 174.52 Million SEK | -6064.627% |
| Senzime AB (publ) | 141.51 Million SEK | -7502.62% |
| SpectraCure AB (publ) | 12.12 Million SEK | -88612.071% |
| Stille AB | 87.21 Million SEK | -12235.615% |
| Vitrolife AB (publ) | 5.56 Billion SEK | -93.264% |
| Xvivo Perfusion AB (publ) | 440.92 Million SEK | -2340.103% |